Request for Information: Comments on the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Draft Strategic Plan, 46000-46001 [2021-17535]

Download as PDF 46000 Federal Register / Vol. 86, No. 156 / Tuesday, August 17, 2021 / Notices injury, condition, or death described in the petition is due to factors unrelated to the administration of the vaccine described in the petition,’’ and 2. Any allegation in a petition that the petitioner either: a. ‘‘[S]ustained, or had significantly aggravated, any illness, disability, injury, or condition not set forth in the Vaccine Injury Table but which was caused by’’ one of the vaccines referred to in the Table, or b. ‘‘[S]ustained, or had significantly aggravated, any illness, disability, injury, or condition set forth in the Vaccine Injury Table the first symptom or manifestation of the onset or significant aggravation of which did not occur within the time period set forth in the Table but which was caused by a vaccine’’ referred to in the Table. In accordance with Section 2112(b)(2), all interested persons may submit written information relevant to the issues described above in the case of the petitions listed below. Any person choosing to do so should file an original and three (3) copies of the information with the Clerk of the United States Court of Federal Claims at the address listed above (under the heading FOR FURTHER INFORMATION CONTACT), with a copy to HRSA addressed to Director, Division of Injury Compensation Programs, Healthcare Systems Bureau, 5600 Fishers Lane, 08N146B, Rockville, Maryland 20857. The Court’s caption (Petitioner’s Name v. Secretary of HHS) and the docket number assigned to the petition should be used as the caption for the written submission. Chapter 35 of title 44, United States Code, related to paperwork reduction, does not apply to information required for purposes of carrying out the Program. Diana Espinosa, Acting Administrator. khammond on DSKJM1Z7X2PROD with NOTICES List of Petitions Filed 1. James Edward Perry, Garden Grove, California, Court of Federal Claims No: 21–1530V 2. Billy Sword, Kingsport, Tennessee, Court of Federal Claims No: 21–1534V 3. Amanda Purdin, Hilliard, Ohio, Court of Federal Claims No: 21–1536V 4. Eileen Arcery, Depew, New York, Court of Federal Claims No: 21–1537V 5. Alex Dosser, Oklahoma City, Oklahoma, Court of Federal Claims No: 21–1538V 6. Rameen Rizi, Phoenix, Arizona, Court of Federal Claims No: 21–1544V 7. Angeline Khan on behalf of A.K., Hayward, California, Court of Federal Claims No: 21–1545V 8. Veronica Mendoza, Juarez, Mexico, Court of Federal Claims No: 21–1547V 9. Jennifer Raftery, Washington, District of Columbia, Court of Federal Claims No: 21–1549V VerDate Sep<11>2014 17:08 Aug 16, 2021 Jkt 253001 10. Meagan Brown Schmidt, Washington, District of Columbia, Court of Federal Claims No: 21–1550V 11. David Shafer, Midland, Texas, Court of Federal Claims No: 21–1552V 12. Darcy Weidner, Sharon, Pennsylvania, Court of Federal Claims No: 21–1554V 13. Olinda Gilmore, Universal City, Texas, Court of Federal Claims No: 21–1556V 14. William L. Miller, Cary, North Carolina, Court of Federal Claims No: 21–1559V 15. Erik Koonce, Doylestown, Pennsylvania, Court of Federal Claims No: 21–1560V 16. Patricia Santiago, Chicago, Illinois, Court of Federal Claims No: 21–1562V 17. Nicholas Politano, Phoenix, Arizona, Court of Federal Claims No: 21–1563V 18. Laura Surface, Northfield, New Jersey, Court of Federal Claims No: 21–1565V 19. Juanita Green, Washington, District of Columbia, Court of Federal Claims No: 21–1566V 20. Claire Kuang, Washington, District of Columbia, Court of Federal Claims No: 21–1567V 21. Kathleen R. McNamee, North Olmstead, Ohio, Court of Federal Claims No: 21– 1568V 22. Katie Perette, Bridgewater, Massachusetts, Court of Federal Claims No: 21–1569V 23. John Wirsen, Springfield, Missouri, Court of Federal Claims No: 21–1571V 24. Raquel Hernandez, Modesto, California, Court of Federal Claims No: 21–1572V 25. Hannah R. Boudreau, Juliet, Tennessee, Court of Federal Claims No: 21–1573V 26. Beverly Hales, Ashland, Texas, Court of Federal Claims No: 21–1575V 27. William McCaughey, Warwick, Rhode Island, Court of Federal Claims No: 21– 1576V 28. Helena Smith on behalf of A.S., Chicago, Illinois, Court of Federal Claims No: 21– 1577V 29. William Minner, Topeka, Kansas, Court of Federal Claims No: 21–1579V 30. Keith A. Lee, New York, New York, Court of Federal Claims No: 21–1582V 31. Bobbi Hoodiman on behalf of T.H., Ridgewood, New Jersey, Court of Federal Claims No: 21–1583V 32. Edward O. Janosko, II, Wilmington, North Carolina, Court of Federal Claims No: 21–1584V 33. Jammie Yerks, Boscobel, Wisconsin, Court of Federal Claims No: 21–1585V 34. Dennis L. Ericson, West Hartford, Connecticut, Court of Federal Claims No: 21–1587V 35. Todd Seely, Washington, District of Columbia, Court of Federal Claims No: 21–1590V 36. Kathleen Pachuki, Chicago, Illinois, Court of Federal Claims No: 21–1591V 37. Madison Jugon, The Woodlands, Texas, Court of Federal Claims No: 21–1592V 38. Brenda Hatten, Omaha, Nebraska, Court of Federal Claims No: 21–1593V 39. Cristian Garcia, Boston, Massachusetts, Court of Federal Claims No: 21–1601V 40. Robert Donchess, Blythewood, South Carolina, Court of Federal Claims No: 21–1603V 41. Luke Kramer, Upland, California, Court of Federal Claims No: 21–1604V PO 00000 Frm 00049 Fmt 4703 Sfmt 4703 42. James Mease, Elkton, Maryland, Court of Federal Claims No: 21–1605V 43. Taylor Williams, Greensboro, North Carolina, Court of Federal Claims No: 21–1606V 44. Frank Burke, Portland, Oregon, Court of Federal Claims No: 21–1607V 45. Paul Pellegrino on behalf of A.P., Matthews, North Carolina, Court of Federal Claims No: 21–1608V 46. Victoria A. Van Voorhis, Rochester, New York, Court of Federal Claims No: 21– 1610V 47. Edna Fowler on behalf of The Estate of William Fowler, Deceased, Dublin, Ohio, Court of Federal Claims No: 21–1611V 48. Morgan Smith, Rock Hill, South Carolina, Court of Federal Claims No: 21–1613V 49. Roger Nyhuis, Cincinnati, Ohio, Court of Federal Claims No: 21–1615V 50. Julia Seeli on behalf of P.S., Phoenix, Arizona, Court of Federal Claims No: 21– 1616V 51. Michelle Foster on behalf of H.F., Phoenix, Arizona, Court of Federal Claims No: 21–1617V 52. Nicholas Delaney and Krystal Delaney on behalf of C.M.D., St. Cloud, Minnesota, Court of Federal Claims No: 21–1620V 53. Cassie Malone, Casper, Wyoming, Court of Federal Claims No: 21–1625V 54. Sarah Lukas, Phoenix, Arizona, Court of Federal Claims No: 21–1627V 55. Jeanne M. Quattromani, Westerly, Rhode Island, Court of Federal Claims No: 21– 1628V 56. Linda Waxman, Lyndhurst, Ohio, Court of Federal Claims No: 21–1631V 57. John D. Slusser, Jr., St. Christiansburg, Virginia, Court of Federal Claims No: 21– 1636V 58. Julia Seeli on behalf of S. H., Phoenix, Arizona, Court of Federal Claims No: 21– 1637V 59. Yvonne Romo, Seattle, Washington, Court of Federal Claims No: 21–1638V [FR Doc. 2021–17557 Filed 8–16–21; 8:45 am] BILLING CODE 4165–15–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Request for Information: Comments on the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Draft Strategic Plan AGENCY: National Institutes of Health, HHS. ACTION: Notice. This Request for Information (RFI) is intended to seek feedback from the public on the draft National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Strategic Plan for Research. NIDDK invites input from: The scientific research community; patients and caregivers; health care providers and health advocacy organizations; scientific and SUMMARY: E:\FR\FM\17AUN1.SGM 17AUN1 Federal Register / Vol. 86, No. 156 / Tuesday, August 17, 2021 / Notices professional organizations; federal agencies; and other stakeholders, including interested members of the public. Organizations are strongly encouraged to submit a single response that reflects the views of their organization and their membership as a whole. DATES: Comments must be received by 11:59:59 p.m. (ET) on August 31, 2021 to ensure consideration. ADDRESSES: All comments must be submitted electronically on the submission website, available at https:// rfi.grants.nih.gov/?s=60fef9beab 43000053007ed2. khammond on DSKJM1Z7X2PROD with NOTICES FOR FURTHER INFORMATION CONTACT: Please direct all inquiries to: Lisa Gansheroff, NIDDKstrategicplan@ nih.gov, 301–496–6623. SUPPLEMENTARY INFORMATION: This Notice is in accordance with the 21st Century Cures Act, NIH institutes are required to regularly update their strategic plans. The NIDDK’s ongoing Institute-wide strategic planning process will develop a broad vision for accelerating research into the causes, prevention, and treatment of diseases and conditions within the Institute’s mission. This overarching trans-NIDDK Strategic Plan will complement NIDDK’s disease-specific planning efforts. The Strategic Plan will have a 5year time horizon but will also include planning for longer term efforts that could be initiated within this time frame. External input has been integral to the strategic planning process. NIDDK established a Working Group of Council, comprised of 44 external scientists and patient advocates, including a subset of the members of NIDDK’s Advisory Council and others with expertise across the range of NIDDK’s mission areas. The Institute also invited broad external input with a public RFI in 2020, and received valuable comments from organizations, individual researchers, people living with diseases in NIDDK’s mission, and others. Based on input from the Working Group, the previous RFI, and Council, the Institute has prepared a draft of the Strategic Plan; the draft will be available for public comment through August 31, 2021 via the new RFI at the link above. NIDDK is committed to empowering a multidisciplinary research community; engaging diverse stakeholders; and leveraging discoveries of connections among diseases across NIDDK’s mission to improve prevention, treatment, and health equity—pursuing pathways to health for all. This theme is addressed throughout the draft strategic plan. VerDate Sep<11>2014 17:08 Aug 16, 2021 Jkt 253001 The draft Strategic Plan includes five major sections: • Advance understanding of biological pathways and environmental contributors to health and disease • Advance pivotal clinical studies and trials for prevention, treatment, and cures in diverse populations • Advance research to disseminate and implement evidence-based prevention strategies and treatments in clinics and community settings, to improve the health of all people, more rapidly and more effectively • Advance stakeholder engagement— including patients and other participants as true partners in research • Promote efficient and effective ways to serve as a trusted steward of public resources and support research for diseases across our mission NIDDK invites comments on the draft Strategic Plan from: The scientific research community; patients and caregivers; health care providers and health advocacy organizations; scientific and professional organizations; federal agencies; and other stakeholders, including interested members of the public. Organizations are strongly encouraged to submit a single response that reflects the views of their organization and membership as a whole. Responses to this RFI are voluntary and may be submitted anonymously. Please do not include any information that you do not wish to make public. Proprietary, classified, confidential, or sensitive information should not be included in your response. The Government will use the information submitted in response to this RFI at its discretion. Individual feedback will not be provided to any responder. The Government reserves the right to use any submitted information on public websites, in reports, in summaries of the state of the science, in any possible resultant solicitation(s), grant(s), or cooperative agreement(s), or in the development of future funding opportunity announcements. This RFI is for informational and planning purposes only and is not a solicitation for applications or an obligation on the part of the Government to provide support for any ideas identified in response to it. Please note that the Government will not pay for the preparation of any information submitted or for use of that information. NIDDK looks forward to your input and we hope that you will share this RFI with your colleagues. PO 00000 Frm 00050 Fmt 4703 Sfmt 4703 46001 Dated: August 11, 2021. Bruce Tibor Roberts, Health Science Policy Analyst, Office of Scientific Program and Policy Analysis, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health. [FR Doc. 2021–17535 Filed 8–16–21; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel; Clinical Trials and Comparative Effectiveness Studies. Date: August 23, 2021. Time: 10:00 a.m. to 5:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Virtual Meeting). Contact Person: Shanta Rajaram, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Activities, NINDS/NIH, NSC, 6001 Executive Blvd., Suite 3208, MSC 9529, Bethesda, MD 20892, (301) 435–6033, rajarams@mail.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. (Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS) Dated: August 11, 2021. Tyeshia M. Roberson-Curtis, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2021–17559 Filed 8–16–21; 8:45 am] BILLING CODE 4140–01–P E:\FR\FM\17AUN1.SGM 17AUN1

Agencies

[Federal Register Volume 86, Number 156 (Tuesday, August 17, 2021)]
[Notices]
[Pages 46000-46001]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-17535]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Request for Information: Comments on the National Institute of 
Diabetes and Digestive and Kidney Diseases (NIDDK) Draft Strategic Plan

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This Request for Information (RFI) is intended to seek 
feedback from the public on the draft National Institute of Diabetes 
and Digestive and Kidney Diseases (NIDDK) Strategic Plan for Research. 
NIDDK invites input from: The scientific research community; patients 
and caregivers; health care providers and health advocacy 
organizations; scientific and

[[Page 46001]]

professional organizations; federal agencies; and other stakeholders, 
including interested members of the public. Organizations are strongly 
encouraged to submit a single response that reflects the views of their 
organization and their membership as a whole.

DATES: Comments must be received by 11:59:59 p.m. (ET) on August 31, 
2021 to ensure consideration.

ADDRESSES: All comments must be submitted electronically on the 
submission website, available at https://rfi.grants.nih.gov/?s=60fef9beab43000053007ed2.

FOR FURTHER INFORMATION CONTACT: Please direct all inquiries to: Lisa 
Gansheroff, [email protected], 301-496-6623.

SUPPLEMENTARY INFORMATION: This Notice is in accordance with the 21st 
Century Cures Act, NIH institutes are required to regularly update 
their strategic plans. The NIDDK's ongoing Institute-wide strategic 
planning process will develop a broad vision for accelerating research 
into the causes, prevention, and treatment of diseases and conditions 
within the Institute's mission. This overarching trans-NIDDK Strategic 
Plan will complement NIDDK's disease-specific planning efforts. The 
Strategic Plan will have a 5-year time horizon but will also include 
planning for longer term efforts that could be initiated within this 
time frame.
    External input has been integral to the strategic planning process. 
NIDDK established a Working Group of Council, comprised of 44 external 
scientists and patient advocates, including a subset of the members of 
NIDDK's Advisory Council and others with expertise across the range of 
NIDDK's mission areas. The Institute also invited broad external input 
with a public RFI in 2020, and received valuable comments from 
organizations, individual researchers, people living with diseases in 
NIDDK's mission, and others. Based on input from the Working Group, the 
previous RFI, and Council, the Institute has prepared a draft of the 
Strategic Plan; the draft will be available for public comment through 
August 31, 2021 via the new RFI at the link above.
    NIDDK is committed to empowering a multidisciplinary research 
community; engaging diverse stakeholders; and leveraging discoveries of 
connections among diseases across NIDDK's mission to improve 
prevention, treatment, and health equity--pursuing pathways to health 
for all. This theme is addressed throughout the draft strategic plan.
    The draft Strategic Plan includes five major sections:
     Advance understanding of biological pathways and 
environmental contributors to health and disease
     Advance pivotal clinical studies and trials for 
prevention, treatment, and cures in diverse populations
     Advance research to disseminate and implement evidence-
based prevention strategies and treatments in clinics and community 
settings, to improve the health of all people, more rapidly and more 
effectively
     Advance stakeholder engagement--including patients and 
other participants as true partners in research
     Promote efficient and effective ways to serve as a trusted 
steward of public resources and support research for diseases across 
our mission
    NIDDK invites comments on the draft Strategic Plan from: The 
scientific research community; patients and caregivers; health care 
providers and health advocacy organizations; scientific and 
professional organizations; federal agencies; and other stakeholders, 
including interested members of the public. Organizations are strongly 
encouraged to submit a single response that reflects the views of their 
organization and membership as a whole.
    Responses to this RFI are voluntary and may be submitted 
anonymously. Please do not include any information that you do not wish 
to make public. Proprietary, classified, confidential, or sensitive 
information should not be included in your response. The Government 
will use the information submitted in response to this RFI at its 
discretion. Individual feedback will not be provided to any responder. 
The Government reserves the right to use any submitted information on 
public websites, in reports, in summaries of the state of the science, 
in any possible resultant solicitation(s), grant(s), or cooperative 
agreement(s), or in the development of future funding opportunity 
announcements. This RFI is for informational and planning purposes only 
and is not a solicitation for applications or an obligation on the part 
of the Government to provide support for any ideas identified in 
response to it. Please note that the Government will not pay for the 
preparation of any information submitted or for use of that 
information. NIDDK looks forward to your input and we hope that you 
will share this RFI with your colleagues.

    Dated: August 11, 2021.
Bruce Tibor Roberts,
Health Science Policy Analyst, Office of Scientific Program and Policy 
Analysis, National Institute of Diabetes and Digestive and Kidney 
Diseases, National Institutes of Health.
[FR Doc. 2021-17535 Filed 8-16-21; 8:45 am]
BILLING CODE 4140-01-P